A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease
- 7 August 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 79 (6), 547-552
- https://doi.org/10.1212/wnl.0b013e318263565f
Abstract
Objective: To compare the respective efficiency of CSF tau (quantitative) and CSF 14-3-3 protein (qualitative) in the diagnosis of prion disease. Methods: We made measurements on 420 live subjects, who subsequently underwent a postmortem neuropathology examination, including protein chemistry, immunohistochemistry, and histology. We performed tau by ELISA. We detected 14-3-3 protein by Western blot. Both assays were optimized for maximum efficiency (accuracy). Results: We found tau and 14-3-3 proteins to be closely correlated, but tau had a significantly better ability to predict disease status than 14-3-3 protein. Also, tau distinguished disease status at least as well as when both assays' results are combined in a variety of ways. Importantly, the area under the receiver operating characteristic curve for tau (0.82) was significantly larger than that for 14-3-3 protein (0.68) (p < 0.001). Diagnostic test statistics are provided for the study subjects with 58.3% prevalence, and for a more typical, nonselected, 7.5% prevalence as received by our center. Conclusion: In this study, tau is superior to 14-3-3 protein as a marker in the diagnosis of Creutzfeldt-Jakob disease, and is as efficient singly compared to a variety of combinations with 14-3-3 protein. This is the first study of this magnitude to examine prion disease diagnostic tests in a carefully characterized patient population with detailed statistical evaluation.Keywords
This publication has 28 references indexed in Scilit:
- Treatable neurological disorders misdiagnosed as Creutzfeldt‐Jakob diseaseAnnals of Neurology, 2011
- Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectivesNature Reviews Drug Discovery, 2010
- The diagnostic efficiency of biomarkers in sporadic Creutzfeldt-Jakob disease compared to Alzheimer's diseaseNeurobiology of Aging, 2009
- 14-3-3 CSF levels in sporadic Creutzfeldt–Jakob disease differ across molecular subtypesNeurobiology of Aging, 2009
- Cerebrospinal fluid markers in Creutzfeldt-Jakob diseaseFluids and Barriers of the CNS, 2008
- Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosisZeitschrift für Neurologie, 2007
- Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt-Jakob diseaseBrain, 2006
- A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Coexistence of 21-Hydroxylase and 11β-Hydroxylase Deficiency in Adrenal Incidentalomas and in Subclinical Cushing’s SyndromeHormone Research in Paediatrics, 2002
- Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjectsAnnals of Neurology, 1999